Swen Hesse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Swen Hesse has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Osama Sabri
Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
5 shared publications Henryk Barthel
Department of Nuclear Medicine, University Hospital, University of Leipzig, Liebigstrae 20A, Leipzig 04103, Germany
3 shared publicationsUlrich Müller
Departments of Experimental Psychology and Psychiatry, University of Cambridge, Cambridge, UK
3 shared publicationsA. Wagner
Clinic for Neurology, University Hospital
2 shared publicationsH. Barthel
Clinic for Nuclear Medicine, University Hospital
2 shared publicationsAnita Seese
University of Leipzig
1 shared publication
Latest Publications
- 6 February 2006
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 113 (9) , 1177-1190
Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome
Single-photon emission computed tomography (SPECT) markers allow measuring the integrity of the brain dopaminergic system in vivo. We used dopamine transporter (DAT) SPECT with [123I]FP-CIT and dopamine D2/D3 receptor SPECT with [123I]IBZM to evaluate whether there is a reduction of DAT and/or D2/D3 receptor SPECT in treated and untreated patients with Parkinsonian syndrome (PS). We found that almost a quarter of our patients treated with anti-Parkinsonian medication prior to SPECT imaging did not show evidence of a presynaptic dopaminergic deficit while 37% of untreated patients were diagnosed as having Parkinson’s disease. 17% of treated patients had additional loss of D2/D3 receptor binding capacity in concordance with the clinical follow-up diagnoses of multiple system atrophy, progressive nuclear palsy, and vascular Parkinsonism. Apart from 38% clinically uncertain cases, SPECT was in concordance with 75% of initial clinical diagnoses. 25% were reclassified as indicated by SPECT findings and confirmed by a 1.5-year clinical follow-up. We conclude that dopamine SPECT may support establishing or refuting the clinical diagnosis and, therefore, help to make the decision for or against dopaminomimetic treatment in cases with PS.
- 6 February 2006
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 113 (9) , 1177-1190
Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome
Single-photon emission computed tomography (SPECT) markers allow measuring the integrity of the brain dopaminergic system in vivo. We used dopamine transporter (DAT) SPECT with [123I]FP-CIT and dopamine D2/D3 receptor SPECT with [123I]IBZM to evaluate whether there is a reduction of DAT and/or D2/D3 receptor SPECT in treated and untreated patients with Parkinsonian syndrome (PS). We found that almost a quarter of our patients treated with anti-Parkinsonian medication prior to SPECT imaging did not show evidence of a presynaptic dopaminergic deficit while 37% of untreated patients were diagnosed as having Parkinson’s disease. 17% of treated patients had additional loss of D2/D3 receptor binding capacity in concordance with the clinical follow-up diagnoses of multiple system atrophy, progressive nuclear palsy, and vascular Parkinsonism. Apart from 38% clinically uncertain cases, SPECT was in concordance with 75% of initial clinical diagnoses. 25% were reclassified as indicated by SPECT findings and confirmed by a 1.5-year clinical follow-up. We conclude that dopamine SPECT may support establishing or refuting the clinical diagnosis and, therefore, help to make the decision for or against dopaminomimetic treatment in cases with PS.
- 31 December 2005
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 29 (7) , 1119
Corrigendum to “Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders”
- 31 December 2005
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 29 (7) , 1119
Corrigendum to “Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders”
- 1 October 2005
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 140 (1) , 63-72
Serotonin and dopamine transporter imaging in patients with obsessive–compulsive disorder
- 1 October 2005
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 140 (1) , 63-72
Serotonin and dopamine transporter imaging in patients with obsessive–compulsive disorder
- 1 October 2004
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 28 (6) , 547-563
Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders
- 1 October 2004
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 28 (6) , 547-563
Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders
- 1 August 2003
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 110 (8) , 923-933
Regional serotonin transporter availability and depression are correlated in Wilson?s disease
In patients with Wilson’s disease (WD), depression is a frequent psychiatric symptom. In vivo neuroimaging studies suggest that depression and other neuropsychiatric disorders are associated with central serotonergic deficits. However, in vivo measurements of serotonergic neurotransmission have not until now been performed in patients with this copper deposition disorder. The present prospective study revealed that depressive symptomatology is related to an alteration of presynaptic serotonin transporters (SERT) availability as measured by [123I]-2β-carbomethoxy-3β-(iodophenyl)tropane ([123I]β-CIT) and high-resolution single-photon emission computed tomography (SPECT). SERT imaging with [123I]β-CIT-SPECT could therefore become a useful tool for diagnosis and therapy monitoring in depressed WD patients.
- 1 August 2003
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 110 (8) , 923-933
Regional serotonin transporter availability and depression are correlated in Wilson?s disease
In patients with Wilson’s disease (WD), depression is a frequent psychiatric symptom. In vivo neuroimaging studies suggest that depression and other neuropsychiatric disorders are associated with central serotonergic deficits. However, in vivo measurements of serotonergic neurotransmission have not until now been performed in patients with this copper deposition disorder. The present prospective study revealed that depressive symptomatology is related to an alteration of presynaptic serotonin transporters (SERT) availability as measured by [123I]-2β-carbomethoxy-3β-(iodophenyl)tropane ([123I]β-CIT) and high-resolution single-photon emission computed tomography (SPECT). SERT imaging with [123I]β-CIT-SPECT could therefore become a useful tool for diagnosis and therapy monitoring in depressed WD patients.
- 16 January 2003
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 30 (3) , 427-430
Is correction for age necessary in neuroimaging studies of the central serotonin transporter?
The central neurotransmitter serotonin plays a major role in a number of neuropsychiatric disorders. However, results from post-mortem and in vivo neuroimaging studies of the influence of age on the number of presynaptic serotonin transporters (SERT) are controversial. To provide further evidence of relevance for this ongoing discussion, SERT were imaged in 22 persons without neuropsychiatric impairment using [123I]2β-carbomethoxy-3β-(iodophenyl)tropane ([123I]β-CIT) and high-resolution single-photon emission tomography (SPET). The SPET analysis method was based on magnetic resonance image co-registration in order to quantify SERT with acceptable inter- and intra-observer variability. Using this technique, we found a significant age-related decline in the thalamic/hypothalamic and midbrain/upper brainstem SERT density, which was more pronounced than that previously reported in the literature. From these results we conclude that age-related changes in SERT density need to be considered in future clinical studies.
- 16 January 2003
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 30 (3) , 427-430
Is correction for age necessary in neuroimaging studies of the central serotonin transporter?
The central neurotransmitter serotonin plays a major role in a number of neuropsychiatric disorders. However, results from post-mortem and in vivo neuroimaging studies of the influence of age on the number of presynaptic serotonin transporters (SERT) are controversial. To provide further evidence of relevance for this ongoing discussion, SERT were imaged in 22 persons without neuropsychiatric impairment using [123I]2β-carbomethoxy-3β-(iodophenyl)tropane ([123I]β-CIT) and high-resolution single-photon emission tomography (SPET). The SPET analysis method was based on magnetic resonance image co-registration in order to quantify SERT with acceptable inter- and intra-observer variability. Using this technique, we found a significant age-related decline in the thalamic/hypothalamic and midbrain/upper brainstem SERT density, which was more pronounced than that previously reported in the literature. From these results we conclude that age-related changes in SERT density need to be considered in future clinical studies.